Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Companion Diagnostics Dilemma

This article was originally published in RPM Report

Executive Summary

An Institute of Medicine workshop on companion diagnostics suggests that regulatory standards are evolving at FDA to encourage companion diagnostic development. But almost everything else is still a challenge.

You may also be interested in...

Time For LUFA? Lab-Developed Test Policy Will Be Key Piece Of 2017 FDA Law

FDA is hoping to set up yet another user fee program—this one for lab-developed test oversight—when the next user fee legislation is enacted in 2017. The labs aren’t ready to negotiate yet, but the issue is going to be an important area for biopharma to monitor as the transition to personalized medicine continues.

One Small Step Towards Personalized Medicine: CMS Reimbursement Changes in “Doc Fix”

CMS is emphasizing coverage of companion diagnostics as a key role it can play in advancing personalized medicine. A couple of add-ons to this year’s “Doc Fix” legislation may help move that effort forward.

Myriad Seeks To Diversify While Remaining Aggressive On BRCA Testing Market

While the genetics firm is not wavering in its legal effort to protect its BRCA gene testing dominance, it is diversifying in response to inevitable competition, with a focus on a multigene panel and companion diagnostics.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts